Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173661 · ClinicalTrials.gov registry record · Phase 4
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
A Phase 4 study of Migraine and Menstrual Migraine, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- Phase 4
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT06173661 is a Phase 4 study of Migraine and Menstrual Migraine that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 72 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06173661, a Phase 4 study of Migraine and Menstrual Migraine, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about how a migraine prevention medicine works for people who have migraines/headaches with their menstrual period. The study includes people ages 18 to 45 who have been diagnosed with migraine and who have a migraine with their menstrual period or those who have migraines with their menstrual period and at other times of the month as well. The main question the study aims to answer are: • Does fremanazemab, an injectable calcitonin gene-related peptide (CGRP) pathway targeting therapy, decrease migraines associated with menstruation? Participants will * have an evaluation and examination by a headache specialist physician * will receive the study medicine or inactive substitute every three months for two treatments * fill out diaries about their migraines * have tests on saliva to measure hormone levels Researchers will compare the people who get the medicine to those who get the inactive substitute to see if there are differences in response.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Fremanezumab
Study Locations (1)
Massachusetts
- Brigham and Women's Health Care Center - Chestnut Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2026-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06173661
The ClinicalTrials.gov registry entry for NCT06173661 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (80% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06173661 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06173661 about?
NCT06173661 is a clinical study titled "Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45". The goal of this clinical trial is to learn about how a migraine prevention medicine works for people who have migraines/headaches with their menstrual period. The study includes people ages 18 to 45 who have been diagnosed with migraine and who have a migraine with their menstrual period or those w...
What is the current status of trial NCT06173661?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2024-03-01. Estimated completion is 2026-07.
What conditions does trial NCT06173661 study?
This clinical trial studies the following conditions: Migraine, Menstrual Migraine, Menstrually Related Migraine.
What interventions are being tested in trial NCT06173661?
The interventions under investigation include: Placebo (OTHER), Fremanezumab (DRUG).
Who is sponsoring clinical trial NCT06173661?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06173661 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.